RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 The RANKL Inhibitor Denosumab Reduces Progression of the Total Sharp Score and Bone Erosions in Patients with Rheumatoid Arthritis
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 4
SP 14
OP 15
DO 10.1177/155989770700700410
UL http://mdc.sagepub.com/content/7/4/14.2.abstract
AB Denosumab is a fully human monoclonal antibody that binds to and inhibits RANK Ligand (RANKL), a key mediator of osteoclast formation, function, and survival. This article discusses an ongoing, double-blind, placebo-controlled, phase 2 study was conducted to determine if denosumab treatment could reduce the progression of bone erosions in patients with RA who were on background methotrexate.